Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice - Episode 17

The Exciting Future of NSCLC Treatment

, , ,

Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.

EP. 1: Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
EP. 2: The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC
EP. 3: Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials
EP. 4: Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC
EP. 5: Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial
EP. 6: The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC
EP. 7: Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC
EP. 8: Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors
EP. 9: CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC
EP. 10: KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC
EP. 11: EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC
EP. 12: POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC
EP. 13: Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy
EP. 14: The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC
EP. 15: The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC
EP. 16: A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations
Now Viewing
EP. 17: The Exciting Future of NSCLC Treatment
EP. 18: Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?
EP. 19: POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations
EP. 20: Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations
EP. 21: Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations
EP. 22: Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations